Comparative Pharmacology
Head-to-head clinical analysis: NEOPASALATE versus PARASAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEOPASALATE versus PARASAL.
NEOPASALATE vs PARASAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Para-aminosalicylic acid (PAS) competitively inhibits the conversion of aminobenzoic acid to dihydrofolate, thereby inhibiting Mycobacterium tuberculosis growth.
Uncertain; may involve inhibition of prostaglandin synthesis in the CNS, weak inhibition of COX-1 and COX-2, and activation of TRPA1 channels.
4-6 g orally twice daily; maximum 12 g/day.
4 g (8 capsules or 2 sachets) orally every 6 hours; maximum 16 g per day.
None Documented
None Documented
Terminal elimination half-life is 2.5–4.5 hours in adults, prolonged in renal impairment.
Terminal half-life: 10-15 hours in adults with normal renal function; prolonged to 20-30 hours in renal impairment.
Primarily renal (≥80% as unchanged drug and acetylated metabolite); minor fecal elimination (<5%).
Renal: 50-60% as unchanged drug; biliary/fecal: 20-30% as metabolites; total recovery: >80% within 24 hours.
Category C
Category C
Antituberculosis Agent
Antituberculosis Agent